The President of Malta

Speech for H.E. George Vella, President of Malta during visit to Aurobindo Pharma Malta

Visit Aurobindo Pharma Malta

Mr Frederick Schembri, Managing Director Employees at Aurobindo Pharma Malta

It is a great pleasure to be with you today and observe up close the diligent and professional work carried out by a dedicated team of experts engaged in a highly technological and medically state of the art facility.

Established in Malta in 2008, operating in over 150 global markets and engaging locally over 170 employees, Aurobindo Pharma Malta is today one of the leading pharmaceutical companies enjoying business successes both locally and at a regional and European level. The highly specialised workforce, including the engagement of professionals from neighbouring and distant countries, continues to enrich the company’s professional portfolio.

The continuous investment in local infrastructure, especially the €3 million project investment in cancer medicine testing introduced in 2019, is a sign of this company’s success, and a vote of confidence in the accommodating business and commercial environment found in our country. It is also a sign of determination to continue to be one of the top 10 leading pharmaceutical manufacturing companies in the world.

The company’s role in testing of oncology drugs, together with other specialized services, linked to pharmacovigilance and regulatory affairs, highlight Aurobindo’s overarching ethos of being a leader in fast and efficient product analysis.

In the year 2020 and the first quarter of 2021 the world continues to fight an uphill battle to attenuate the spread of the Covid-19 virus. From closure of schools to places of entertainment, the continuous struggle to address this novel global challenge changed radically our daily routines, workspaces and intimate relationships.

Aurobindo Pharma Malta too had to adapt to these new realities, especially to facilitate remote working for its employees. I greatly appreciate the company’s cooperation and adherence with the Maltese health department guidelines, particularly the introduction of remote working and a virtual platform for routine meetings and visits. Although this technological upgrade comes at a cost, I am pleased to observe that the current disruption by the pandemic did not deter the management from taking strong decisions to invest in IT hardware to safeguard the well-being of employees without negatively impacting commercial and business operations.

It is also very encouraging to observe that Aurobindo Pharma Malta is cooperating with other companies in the collective endeavour to develop effective, affordable and available vaccines for all. Thus, ensuring all citizens of the world, particularly those hailing from developing and social-economically disadvantaged countries, have equal access to vaccines and medicines that could counter-act the disastrous social, economic and health effects caused by Covid.

In conclusion, I take the opportunity to thank you all for your work and contribution in the pharmacological industry. The development of new medicine and diligent testing to ensure all health and safety parameters are being observed is key to instil confidence in patients that require the treatment. Through greater distribution of life saving medicines, especially in developing and poor countries, Aurobindo Pharma Malta is contributing to ensure that global health operates in a more just, affordable, and accessible environment.

I wish you all future success.

Skip to content